JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering…
GlobeNewswire 2021-12-20 A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45…
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering…
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering…
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering…
A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45% of commercially insured…
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering…
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative…
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc., (NASDAQ: SCYX), a biotechnology company pioneering…
Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological…
SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG…
Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological…
Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological…
Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological…
Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological…
GlobeNewswire 2021-10-21 In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical…
-- Post hoc analysis found ibrexafungerp demonstrated consistent efficacy in important patient sub-populations, characterized…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection…
JERSEY CITY, N.J. - (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to…
JERSEY CITY, N.J., Oct. 13, 2021 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…
JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:), a biotechnology company pioneering innovative…
JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc., (NASDAQ: SCYX), a biotechnology company pioneering…
JERSEY CITY, N.J. - (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to…
BREXAFEMME is a truly new, first-in-class fungicidal triterpenoid antifungal, designed to kill the yeast causing the infection…
GlobeNewswire 2021-09-22 First and only oral non-azole treatment option approved for vaginal yeast infections is now available…
First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including…
In this article: BREXAFEMME® (ibrexafungerp tablets) Product Image #1 BREXAFEMME® (ibrexafungerp tablets) Package Image #2…
First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including…
First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including…
First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including…